NY-HCLTECH
15.5.2023 17:07:30 CEST | Business Wire | Press release
HCLTech, a leading global technology company, announced the expansion of its long-standing partnership with SAP to drive digital transformation for enterprises.
As part of the expanded collaboration, HCLTech has become a customer of and a global strategic service partner for SAP SuccessFactors Human Experience Management Suite (SAP SuccessFactors HXM Suite).
HCLTech will deploy the SAP SuccessFactors HXM Suite to enhance the experience of its 225,000+ people across the globe and make its recruitment and onboarding processes more agile. HCLTech will also leverage SAP’s Workzone as well as Qualtrics solutions to add to its employee experience.
As a multifaceted SAP partner, HCLTech will also enable enterprises globally to leverage SAP SuccessFactors HXM Suite along with its array of industry leading cloud offerings under CloudSMART.
“Our people are at the core of our growth strategy and we are committed to supercharging their progress. We are delighted to expand our partnership with SAP to continue elevating the experience for our people through the best of technology,” said C Vijayakumar, CEO and Managing Director, HCLTech. “This collaboration also provides us the opportunity to help our clients elevate their employee experience through SAP HXM as part of their digital transformation agenda.”
“As an early adopter and partner of RISE with SAP, HCLTech understands that the successful transformation of any business always starts with its people,” said Christian Klein, CEO and Member of the Executive Board of SAP SE. “We are confident that HCLTech’s selection of SAP’s SuccessFactors HXM Suite, including a strong services component, will further deepen our partnership and drive value for customers worldwide.”
About HCLTech
HCLTech is a global technology company, home to more than 225,900 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG, and Public Services. Consolidated revenues as of 12 months ending March 2023 totaled $12.6 billion. To learn how we can supercharge progress for you, visit hcltech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005588/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
Roboverse Reply Impresses at ELROB 2026 With Intelligent Robotic Systems for Critical Missions26.6.2026 10:00:00 CEST | Press release
Roboverse Reply, the Reply Group company specializing in robotics and automation, won the 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial (ELROB) 2026 in Thun, Switzerland. Teaming up with ELP, a specialist for technical equipment for defusing service, the company demonstrated outstanding performance alongside a field of international participants from June 15 to 19, proving that its autonomous solutions operate reliably under real-world conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626012237/en/ Roboverse Reply won 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial 2026, proving that its autonomous solutions operate reliably under real-world conditions. ELROB is Europe’s most demanding and established showcase for robotics and unmanned systems, where leading experts from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom